Prognostic Value of Reduced SMAD4 Expression in Patients With Metastatic Colorectal Cancer Under Oxaliplatin-Containing Chemotherapy: A Translational Study of the AIO Colorectal Study Group
- 1 March 2011
- journal article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 10 (1), 24-29
- https://doi.org/10.3816/ccc.2011.n.003
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Tissue Biomarker Development in a Multicentre Trial Context: a Feasibility Study on the PETACC3 Stage II and III Colon Cancer Adjuvant Treatment TrialClinical Cancer Research, 2009
- Long-Term Survivors of Metastatic Colorectal Cancer Treated with Systemic Chemotherapy Alone: A North Central Cancer Treatment Group Review of 3811 Patients, N0144Clinical Colorectal Cancer, 2009
- A study of lymph node ratio in stage IV colorectal cancerWorld Journal of Surgical Oncology, 2008
- Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study GroupJournal of Clinical Oncology, 2007
- Estimates of the cancer incidence and mortality in Europe in 2006Annals of Oncology, 2007
- Management of advanced colorectal cancer: state of the artBritish Journal of Cancer, 2006
- A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancerBritish Journal of Surgery, 2006
- Systemic Therapy for Colorectal CancerThe New England Journal of Medicine, 2005
- Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapyAnnals of Oncology, 2003
- Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patientsAnnals of Oncology, 2002